Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 327

Sort by

Sort Order Select

Journal Articles

A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD

Blood (2025) 145 (24): 2857–2872.

https://doi.org/10.1182/blood.2024026581

Published: 2025

Includes: Supplemental data

Journal Articles

Targeting Mitophagy Enhances Cytotoxicity of Autologously-Derived CAR-T Cells

Rongrong Chen, Mingming Zhang, Xufeng Cen, Chunxiang Jin, Yi Luo, Hongguang Xia, Rongqing Pan, He Huang, Yongxian Hu

Blood (2024) 144 (Supplement 1): 7137.

https://doi.org/10.1182/blood-2024-203326

Published: 2024

Journal Articles

A Multicenter Randomized Controlled Trial of Low-Dose Ruxolitinib for Gvhd Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation

Hengwei Wu, Jimin Shi, Yi Luo, Jian Yu, Huarui Fu, Lizhen Liu, Xiaoyu Lai, Luxin Yang, Yishan Ye, Congxiao Zhang, Weijie Cao, Junjie Cao, Xiaojun Xu, Xiaoxia Hu, Ying Lu, He Huang, Yanmin Zhao

Blood (2024) 144 (Supplement 1): 1044.

https://doi.org/10.1182/blood-2024-206823

Published: 2024

Journal Articles

Long-Term Follow-up of Sequential Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients Achieving MRD-Negative CR after CAR-T Therapy

Blood (2024) 144 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2024-209418

Published: 2024

Journal Articles

Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy?

Blood (2024) 144 (Supplement 1): 7418.

https://doi.org/10.1182/blood-2024-206153

Published: 2024

Journal Articles

1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust in vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Yongxian Hu, Mingming Zhang, Shan Fu, Ruimin Hong, Jiazhen Cui, Simao Huang, Min Gao, Daojun Bai, Jingjing Ren, Xingbing Wang, Yugang Guo, Li Tang, He Huang

Blood (2024) 144 (Supplement 1): 2074.

https://doi.org/10.1182/blood-2024-207694

Published: 2024

Journal Articles

Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Tingting Yang, Yetian Dong, Mingming Zhang, Jingjing Feng, Shan Fu, Pingnan Xiao, Ruimin Hong, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Chang, He Huang, Yongxian Hu

Blood (2024) 144 (Supplement 1): 2818.

https://doi.org/10.1182/blood-2024-210124

Published: 2024

Journal Articles

CD19 CAR-T Therapy for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia: A Multicenter Study

Jinglei Yu, Fengmei Song, Mingming Zhang, Mingfeng Zhao, Wei Sang, Songfu Jiang, Lixin Wang, Xingbing Wang, He Huang, Yongxian Hu, Guoqing Wei

Blood (2024) 144 (Supplement 1): 4201.

https://doi.org/10.1182/blood-2024-210616

Published: 2024

Journal Articles

Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 2171.

https://doi.org/10.1182/blood-2024-212040

Published: 2024

Journal Articles

Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

Blood (2024) 144 (Supplement 1): 1739.

https://doi.org/10.1182/blood-2024-192979

Published: 2024

Journal Articles

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Chunrui Li, Dehui Zou, Di Wang, Baijun Fang, He Huang, Jianyong Li, Bing Chen, Jing Liu, Xi Zhang, Yujun Dong, Kai Hu, Peng Liu, Jianqing Mi, Kaiyang Ding, Zhenyu Li, Qie Dong, Fuyuan Zhang, Guang Hu, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2024-204355

Published: 2024

Journal Articles

Lysosome Acidification Facilitates the Expansion of Circulating Hematopoietic Stem and Progenitor Cells

Xu Yulin, Meng Zhang, Jianghuan Lu, Dawei Huo, Penglei Jiang, Ruxiu Tie, Yijin Chen, Xiangjun Zeng, Pengxu Qian, He Huang

Blood (2024) 144 (Supplement 1): 5612.

https://doi.org/10.1182/blood-2024-206973

Published: 2024

Journal Articles

Clinical and Genetic Landscape of Peripheral T-Cell Lymphomas in Chinese Population: A Retrospective Study

Lingling Wang, Lei Yang, Fangshu Guan, Jing Chen, Yuexin Cheng, Yuqing Miao, Jingsong He, Zhen Cai, He Huang, Yi Zhao

Blood (2024) 144 (Supplement 1): 6181.

https://doi.org/10.1182/blood-2024-199127

Published: 2024

Journal Articles

Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2024) 144 (Supplement 1): 3562.

https://doi.org/10.1182/blood-2024-200458

Published: 2024

Journal Articles

Application of 18F-Fapi PET/MRI in the Assessment of Myelofibrosis: A Multi-Center Prospective Observational Study

Dan Tian, Jun Zhang, Yuanyuan Zhu, Weijia Huang, Jin Zhang, He Huang, Xinhui Su, Jie Sun

Blood (2024) 144 (Supplement 1): 3599.

https://doi.org/10.1182/blood-2024-207873

Published: 2024

Journal Articles

The Mutated of KRAS gene Determine the Fate of KMT2A-Rearranged AML Patients

Yibo Wu, Xiaolin Yuan, Xiaoyu Lai, Lizhen Liu, Jimin Shi, Weiyan Zheng, Jian Yu, Yanmin Zhao, Jie Sun, Xiujin Ye, Zhen Cai, He Huang, Shanshan Pei, Yi Luo

Blood (2024) 144 (Supplement 1): 843.

https://doi.org/10.1182/blood-2024-209592

Published: 2024

Journal Articles

IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies

Yugang Guo, Qianwen Xu, Lei Xue, Erlin Chen, Xuhan Zhang, Chonglin Liu, Min Gao, Youjia Li, Jingjing Ren, Karthik Sathiyanadan, Li Tang, He Huang, Yongxian Hu, Xingbing Wang

Blood (2024) 144 (Supplement 1): 92.

https://doi.org/10.1182/blood-2024-206439

Published: 2024

Journal Articles

Rituximab, Lenalidomide, and Zanubrutinib (ZR 2) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma

Mingming Zhang, Yongxian Hu, Guoqing Wei, Shan Fu, Jingjing Feng, Ruimin Hong, Alex H. Chang, He Huang

Blood (2024) 144 (Supplement 1): 91.

https://doi.org/10.1182/blood-2024-210462

Published: 2024

Journal Articles

A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 2879.

https://doi.org/10.1182/blood-2024-198959

Published: 2024

Journal Articles

Clinical Characteristics and Outcomes of BCMA-Targeted CAR-T Cell Recipients with Coronavirus Disease 2019 during the Omicron Wave: A Retrospective Study

Haiqiong Zheng, Shi Han, Houli Zhao, Yongxian Hu, He Huang

Blood (2024) 144 (Supplement 1): 5170.1.

https://doi.org/10.1182/blood-2024-207233

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD

Targeting Mitophagy Enhances Cytotoxicity of Autologously-Derived CAR-T Cells

A Multicenter Randomized Controlled Trial of Low-Dose Ruxolitinib for Gvhd Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation

Long-Term Follow-up of Sequential Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients Achieving MRD-Negative CR after CAR-T Therapy

Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy?

1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust in vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

CD19 CAR-T Therapy for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia: A Multicenter Study

Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Lysosome Acidification Facilitates the Expansion of Circulating Hematopoietic Stem and Progenitor Cells

Clinical and Genetic Landscape of Peripheral T-Cell Lymphomas in Chinese Population: A Retrospective Study

Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Application of 18F-Fapi PET/MRI in the Assessment of Myelofibrosis: A Multi-Center Prospective Observational Study

The Mutated of KRAS gene Determine the Fate of KMT2A-Rearranged AML Patients

IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies

Rituximab, Lenalidomide, and Zanubrutinib (ZR 2) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma

A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN104 in Adult Patients with Relapsed or Refractory Acute Leukemia

Clinical Characteristics and Outcomes of BCMA-Targeted CAR-T Cell Recipients with Coronavirus Disease 2019 during the Omicron Wave: A Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only